These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 38172595)

  • 1. 4-1BB immunotherapy: advances and hurdles.
    Singh R; Kim YH; Lee SJ; Eom HS; Choi BK
    Exp Mol Med; 2024 Feb; 56(1):32-39. PubMed ID: 38172595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies.
    Chester C; Sanmamed MF; Wang J; Melero I
    Blood; 2018 Jan; 131(1):49-57. PubMed ID: 29118009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy of cancer with 4-1BB.
    Vinay DS; Kwon BS
    Mol Cancer Ther; 2012 May; 11(5):1062-70. PubMed ID: 22532596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function.
    Buchan SL; Dou L; Remer M; Booth SG; Dunn SN; Lai C; Semmrich M; Teige I; Mårtensson L; Penfold CA; Chan HTC; Willoughby JE; Mockridge CI; Dahal LN; Cleary KLS; James S; Rogel A; Kannisto P; Jernetz M; Williams EL; Healy E; Verbeek JS; Johnson PWM; Frendéus B; Cragg MS; Glennie MJ; Gray JC; Al-Shamkhani A; Beers SA
    Immunity; 2018 Nov; 49(5):958-970.e7. PubMed ID: 30446386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting 4-1BB for tumor immunotherapy from bench to bedside.
    Wang YT; Ji WD; Jiao HM; Lu A; Chen KF; Liu QB
    Front Immunol; 2022; 13():975926. PubMed ID: 36189243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
    Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
    J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy.
    Vinay DS; Kwon BS
    BMB Rep; 2014 Mar; 47(3):122-9. PubMed ID: 24499671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.
    Curran MA; Kim M; Montalvo W; Al-Shamkhani A; Allison JP
    PLoS One; 2011 Apr; 6(4):e19499. PubMed ID: 21559358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1.
    Enell Smith K; Fritzell S; Nilsson A; Barchan K; Rosén A; Schultz L; Varas L; Säll A; Rose N; Håkansson M; von Schantz L; Ellmark P
    Cancer Immunol Immunother; 2023 Dec; 72(12):4145-4159. PubMed ID: 37796298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses.
    Menk AV; Scharping NE; Rivadeneira DB; Calderon MJ; Watson MJ; Dunstane D; Watkins SC; Delgoffe GM
    J Exp Med; 2018 Apr; 215(4):1091-1100. PubMed ID: 29511066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy.
    Claus C; Ferrara-Koller C; Klein C
    MAbs; 2023; 15(1):2167189. PubMed ID: 36727218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity.
    Compte M; Harwood SL; Erce-Llamazares A; Tapia-Galisteo A; Romero E; Ferrer I; Garrido-Martin EM; Enguita AB; Ochoa MC; Blanco B; Oteo M; Merino N; Nehme-Álvarez D; Hangiu O; Domínguez-Alonso C; Zonca M; Ramírez-Fernández A; Blanco FJ; Morcillo MA; Muñoz IG; Melero I; Rodriguez-Peralto JL; Paz-Ares L; Sanz L; Alvarez-Vallina L
    Clin Cancer Res; 2021 Jun; 27(11):3167-3177. PubMed ID: 33785484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agonism of 4-1BB for immune therapy: a perspective on possibilities and complications.
    Salek-Ardakani S; Zajonc DM; Croft M
    Front Immunol; 2023; 14():1228486. PubMed ID: 37662949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carcinoembryonic Antigen (CEA)-Specific 4-1BB-Costimulation Induced by CEA-Targeted 4-1BB-Agonistic Trimerbodies.
    Mikkelsen K; Harwood SL; Compte M; Merino N; Mølgaard K; Lykkemark S; Alvarez-Mendez A; Blanco FJ; Álvarez-Vallina L
    Front Immunol; 2019; 10():1791. PubMed ID: 31417564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-1BB agonism: adding the accelerator to cancer immunotherapy.
    Chester C; Ambulkar S; Kohrt HE
    Cancer Immunol Immunother; 2016 Oct; 65(10):1243-8. PubMed ID: 27034234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39
    Leem G; Park J; Jeon M; Kim ES; Kim SW; Lee YJ; Choi SJ; Choi B; Park S; Ju YS; Jung I; Kim S; Shin EC; Lee JY; Park SH
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33335029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab.
    Chin SM; Kimberlin CR; Roe-Zurz Z; Zhang P; Xu A; Liao-Chan S; Sen D; Nager AR; Oakdale NS; Brown C; Wang F; Yang Y; Lindquist K; Yeung YA; Salek-Ardakani S; Chaparro-Riggers J
    Nat Commun; 2018 Nov; 9(1):4679. PubMed ID: 30410017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.
    Chen S; Lee LF; Fisher TS; Jessen B; Elliott M; Evering W; Logronio K; Tu GH; Tsaparikos K; Li X; Wang H; Ying C; Xiong M; VanArsdale T; Lin JC
    Cancer Immunol Res; 2015 Feb; 3(2):149-60. PubMed ID: 25387892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity.
    Compte M; Harwood SL; Muñoz IG; Navarro R; Zonca M; Perez-Chacon G; Erce-Llamazares A; Merino N; Tapia-Galisteo A; Cuesta AM; Mikkelsen K; Caleiras E; Nuñez-Prado N; Aznar MA; Lykkemark S; Martínez-Torrecuadrada J; Melero I; Blanco FJ; Bernardino de la Serna J; Zapata JM; Sanz L; Alvarez-Vallina L
    Nat Commun; 2018 Nov; 9(1):4809. PubMed ID: 30442944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.
    Roselli E; Boucher JC; Li G; Kotani H; Spitler K; Reid K; Cervantes EV; Bulliard Y; Tu N; Lee SB; Yu B; Locke FL; Davila ML
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.